Health Catalyst NASDAQ: HCAT reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.